SEC Comment Letter 0000000000-22-013630 to AEON Biopharma, Inc. (AEON) (CIK 0001837607) (AEON)
AEON Biopharma, Inc. (AEON) (CIK 0001837607)
Date: Dec. 19, 2022 · CIK: 0001837607 · Accession: 0000000000-22-013630
AI Filing Summary & Sentiment
File numbers found in text: 001-40021
Letter
United States securities and exchange commission logo December 19, 2022 Oleg Grodnensky Chief Operating Officer Priveterra Acquisition Corp. 300 SE 2nd Street, Suite 600 Fort Lauderdale, FL 33301 Re:Priveterra Acquisition Corp. Preliminary Proxy Statement on Schedule 14A Filed December 13, 2022 File No. 001-40021 Dear Oleg Grodnensky: We have reviewed your filing and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Preliminary Proxy Statement on Schedule 14A General 1.With a view toward disclosure, please tell us whether your sponsor is, is controlled by, or has substantial ties with a non-U.S. person. If so, also include risk factor disclosure that addresses how this fact could impact your ability to complete your initial business combination. For instance, discuss the risk to investors that you may not be able to complete an initial business combination with a U.S. target company should the transaction be subject to review by a U.S. government entity, such as the Committee on Foreign Investment in the United States (CFIUS), or ultimately prohibited. Disclose that as a result, the pool of potential targets with which you could complete an initial business combination may be limited. Further, disclose that the time necessary for government review of the transaction or a decision to prohibit the transaction could prevent you from completing an initial business combination and require you to liquidate. Disclose the consequences of liquidation to investors, such as the losses of the investment opportunity
FirstName LastNameOleg Grodnensky Comapany NamePriveterra Acquisition Corp. December 19, 2022 Page 2 FirstName LastName Oleg Grodnensky Priveterra Acquisition Corp. December 19, 2022 Page 2
in a target company, any price appreciation in the combined company, and the warrants which would expire worthless. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Victor Rivera Melendez at 202-551-4182 or Jeffrey Gabor at 202-551- 2544 with any questions. Sincerely, Division of Corporation Finance Office of Real Estate & Construction cc: W. Soren Kreider IV
Show Raw Text
United States securities and exchange commission logo
December 19, 2022
Oleg Grodnensky
Chief Operating Officer
Priveterra Acquisition Corp.
300 SE 2nd Street, Suite 600
Fort Lauderdale, FL 33301
Re:Priveterra Acquisition Corp.
Preliminary Proxy Statement on Schedule 14A
Filed December 13, 2022
File No. 001-40021
Dear Oleg Grodnensky:
We have reviewed your filing and have the following comment. In our comment, we may
ask you to provide us with information so we may better understand your disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A
General
1.With a view toward disclosure, please tell us whether your sponsor is, is controlled by, or
has substantial ties with a non-U.S. person. If so, also include risk factor disclosure that
addresses how this fact could impact your ability to complete your initial business
combination. For instance, discuss the risk to investors that you may not be able to
complete an initial business combination with a U.S. target company should the
transaction be subject to review by a U.S. government entity, such as the Committee on
Foreign Investment in the United States (CFIUS), or ultimately prohibited. Disclose that
as a result, the pool of potential targets with which you could complete an initial business
combination may be limited. Further, disclose that the time necessary for government
review of the transaction or a decision to prohibit the transaction could prevent you from
completing an initial business combination and require you to liquidate. Disclose the
consequences of liquidation to investors, such as the losses of the investment opportunity
FirstName LastNameOleg Grodnensky
Comapany NamePriveterra Acquisition Corp.
December 19, 2022 Page 2
FirstName LastName
Oleg Grodnensky
Priveterra Acquisition Corp.
December 19, 2022
Page 2
in a target company, any price appreciation in the combined company, and the
warrants which would expire worthless.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Victor Rivera Melendez at 202-551-4182 or Jeffrey Gabor at 202-551-
2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction
cc: W. Soren Kreider IV